Steve Hahn didn't apply for the job of Chief Operating Officer at MD Anderson Cancer Center. In fact, there was no COO job to apply to, and conversations that preceded the announcement of his new role took less than a week.
Due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed.
FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Novartis said FDA has accepted the company's supplemental New Drug Application for filing, and granted Priority Review for the expanded use of Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
Mylan N.V. and Biocon Ltd. said the FDA has accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), for filing through the 351(k) pathway.
MIODx said it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco.
The new Cleveland Clinic Taussig Cancer Center will begin welcoming patients March 6.
Jeffrey Patrick was named director of the Drug Development Institute at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Moonshot appropriations are not a substitute for sustained increases in appropriations, NCI Acting Director Doug Lowy said at the meeting of the National Cancer Advisory Board Feb. 15.
Marcia Crosse: This “failure of the adverse event reporting system” should serve as a “wake up call”
Hundreds of women were injured or have died from upstaging of unsuspected uterine cancer by power morcellation because FDA didn’t know the actual risk of cancer in fibroids, and hospitals failed to report harm, according to the U.S. Government Accountability Office.Between 1991 and 2014, FDA cleared 25 submissions for power morcellators to be marketed in the U.S. The GAO report notes that FDA had been aware of the device's potential for spreading tissue since 1991.
